<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03138889</url>
  </required_header>
  <id_info>
    <org_study_id>16-214-05</org_study_id>
    <nct_id>NCT03138889</nct_id>
  </id_info>
  <brief_title>Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors</brief_title>
  <acronym>PROPEL</acronym>
  <official_title>A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab With or Without Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nektar Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nektar Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety and tolerability, and to assess the preliminary clinical&#xD;
      benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA®) with or without&#xD;
      chemotherapy.&#xD;
&#xD;
      The study is comprised of two groups; dose optimization and dose expansion cohorts.&#xD;
&#xD;
      Dose Optimization included first-line and second-line advanced or metastatic solid tumors&#xD;
      including non-small cell lung cancer (NSCLC)&#xD;
&#xD;
      The dose expansion cohort will include first-line NSCLC patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NKTR-214 is a cytokine (investigational agent) that is designed to target CD122, a protein&#xD;
      which is found on certain immune cells (known as CD8+ T Cells and Natural Killer Cells) to&#xD;
      expand these cells to promote their anti-tumor effects. Pembrolizumab is a programmed death&#xD;
      receptor -1 (PD-1) blocking, fully humanized, engineered monoclonal antibody of IgG1 isotype&#xD;
      that promotes anti-tumor effects.&#xD;
&#xD;
      The study will evaluate the clinical benefit, safety and tolerability of combining NKTR-214&#xD;
      with pembrolizumab with or without chemotherapy. Each dose expansion cohort will enroll&#xD;
      approximately 100 new patients.&#xD;
&#xD;
      Dose Optimization evaluated an every three-week dose regimen (q3w) of NKTR-214 in combination&#xD;
      with pembrolizumab given that the optimal dose and dosing schedule of NKTR-214 in combination&#xD;
      with pembrolizumab remains unknown. The previously established recommended Phase 2 dose&#xD;
      (0.006 mg/kg) of NKTR-214 was studied in combination with nivolumab.&#xD;
&#xD;
      Dose Expansion: NKTR-214 in combination with pembrolizumab will be evaluated in first-line&#xD;
      non-small cell lung cancer (NSCLC). The NKTR-214 dose to be studied is 0.006 mg/kg q3w. This&#xD;
      dose is based on the recommended phase 2 dose noted in the monotherapy trial with NKTR-214&#xD;
      (Study 15-214-01, NCT02869295) and an ongoing combination trial (16-214-02, NCT02983045).&#xD;
      Pembrolizumab will be administered at a dose of 200mg q3w. Following data review for safety&#xD;
      and efficacy, additional patients may be dosed using the findings from the dose optimization&#xD;
      cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2017</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of NKTR-214 in combination with pembrolizumab (Keytruda®)</measure>
    <time_frame>100 days after last dose</time_frame>
    <description>Safety and Tolerability of NKTR-214 in combination with pembrolizumab (Keytruda®) as evaluated by incidence of drug-emergent Adverse Events (AEs), Serious Adverse Events (SAEs), AEs leading to drug discontinuation, and fatal AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) or Maximum Tolerated Dose (MTD) or optimal dosing schedule of NKTR-214 in combination with pembrolizumab (Keytruda®)</measure>
    <time_frame>100 days after last dose</time_frame>
    <description>To define the Recommended Phase 2 Dose (RP2D), or Maximum Tolerated Dose (MTD), or optimal dosing schedule of NKTR-214 in combination with pembrolizumab (Keytruda®), by evaluating the incidence of Dose Limiting Toxicities (DLTs) within the DLT window (21 days after first dose), drug-related AEs, SAEs, adverse events leading to discontinuation, deaths and overall tolerability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) per blinded independent central review (BICR) by RECIST 1.1 of NKTR-214 plus pembrolizumab with or without systemic chemotherapy in patients with untreated metastatic NSCLC</measure>
    <time_frame>100 days after last dose</time_frame>
    <description>ORR is defined as the proportion of enrolled participants who achieved a Best Overall Response (BOR) of CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to &lt; 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR is calculated as the sum of CR and PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of NKTR-214 plus pembrolizumab (Keytruda®) with or without systemic chemotherapy in untreated metastatic NSCLC.</measure>
    <time_frame>100 days after last dose</time_frame>
    <description>Safety and Tolerability of NKTR-214 plus pembrolizumab (Keytruda®) with or without systemic chemotherapy as evaluated by incidence of drug-related Adverse Events (AEs), Serious Adverse Events (SAEs), and adverse events leading to discontinuation, deaths, and overall tolerability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) per RECIST 1.1 in Dose Optimization</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
    <description>ORR is defined as the proportion of enrolled participants who achieved a Best Overall Response (BOR) of CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to &lt; 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR is calculated as the sum of CR and PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) using RECIST 1.1</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
    <description>DOR for patients who have confirmed complete response (CR) or confirmed partial response (PR) as the date from first documented CR or PR to the date of the first objectively documented disease progression per RECIST 1.1 or death due to any cause, whichever is earlier. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to &lt; 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR) using RECIST 1.1</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
    <description>CBR is defined as the number of patients with confirmed complete response, confirmed partial response, or stable disease (≥ 7 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) using RECIST 1.1</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
    <description>TTR will be defined for patients who had confirmed CR or confirmed PR as the time from the date of first dose to date of first documented CR or PR per RECIST 1.1. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to &lt; 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) using RECIST 1.1</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
    <description>PFS is defined as the time from date of first dose to the date of the first objectively documented tumor progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
    <description>OS is defined as the time from date of first dose to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the association between efficacy measures and PD L1 expression in tumors.</measure>
    <time_frame>Through study completion, an expected average of 2 years</time_frame>
    <description>Efficacy measures are defined as ORR and changes in PD-L1 expression from on treatment biopsy in Dose Optimization.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Optimization, Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: NKTR-214 will be combined with pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion, Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: NKTR-214 will be combined with pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion, Combo of NKTR-214 + Pembrolizumab (KEYTRUDA®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3: NKTR-214 will be combined with pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion, NKTR-214 + Pembrolizumab and either Cisplatin, or Carboplatin and Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4: NKTR-214 will be dosed in combination with pembrolizumab and either cisplatin, or carboplatin and pemetrexed, per investigator discretion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion, NKTR-214 + Pembrolizumab and Carboplatin and either Nab-paclitaxel or Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5: NKTR-214 will be dosed in combination with pembrolizumab and carboplatin and either nab-paclitaxel or paclitaxel, per investigator discretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NKTR-214</intervention_name>
    <description>NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.</description>
    <arm_group_label>Dose Optimization, Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®)</arm_group_label>
    <other_name>CD122-Biased Cytokine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.</description>
    <arm_group_label>Dose Expansion, Combo of NKTR-214 + Pembrolizumab (KEYTRUDA®)</arm_group_label>
    <arm_group_label>Dose Expansion, Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®)</arm_group_label>
    <arm_group_label>Dose Expansion, NKTR-214 + Pembrolizumab and Carboplatin and either Nab-paclitaxel or Paclitaxel</arm_group_label>
    <arm_group_label>Dose Expansion, NKTR-214 + Pembrolizumab and either Cisplatin, or Carboplatin and Pemetrexed</arm_group_label>
    <arm_group_label>Dose Optimization, Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®)</arm_group_label>
    <other_name>Keytruda®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NKTR-214</intervention_name>
    <description>NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.</description>
    <arm_group_label>Dose Expansion, Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®)</arm_group_label>
    <arm_group_label>Dose Expansion, NKTR-214 + Pembrolizumab and Carboplatin and either Nab-paclitaxel or Paclitaxel</arm_group_label>
    <arm_group_label>Dose Expansion, NKTR-214 + Pembrolizumab and either Cisplatin, or Carboplatin and Pemetrexed</arm_group_label>
    <other_name>CD122-Biased Cytokine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NKTR-214</intervention_name>
    <description>NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.</description>
    <arm_group_label>Dose Expansion, Combo of NKTR-214 + Pembrolizumab (KEYTRUDA®)</arm_group_label>
    <other_name>CD122-Biased Cytokine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin will be dosed per the pharmacy manual</description>
    <arm_group_label>Dose Expansion, NKTR-214 + Pembrolizumab and either Cisplatin, or Carboplatin and Pemetrexed</arm_group_label>
    <other_name>Platinol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin will be dosed per the pharmacy manual</description>
    <arm_group_label>Dose Expansion, NKTR-214 + Pembrolizumab and Carboplatin and either Nab-paclitaxel or Paclitaxel</arm_group_label>
    <arm_group_label>Dose Expansion, NKTR-214 + Pembrolizumab and either Cisplatin, or Carboplatin and Pemetrexed</arm_group_label>
    <other_name>Paraplatin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab paclitaxel</intervention_name>
    <description>Nab-paclitaxel will be dosed per local practice and label</description>
    <arm_group_label>Dose Expansion, NKTR-214 + Pembrolizumab and Carboplatin and either Nab-paclitaxel or Paclitaxel</arm_group_label>
    <other_name>Abraxane®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel will be dosed per local practice and label</description>
    <arm_group_label>Dose Expansion, NKTR-214 + Pembrolizumab and Carboplatin and either Nab-paclitaxel or Paclitaxel</arm_group_label>
    <other_name>Taxol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed will be dosed per the pharmacy manual</description>
    <arm_group_label>Dose Expansion, NKTR-214 + Pembrolizumab and either Cisplatin, or Carboplatin and Pemetrexed</arm_group_label>
    <other_name>Alimta®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Dose Optimization and Dose Expansion Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent.&#xD;
&#xD;
          -  Male or female patients, age 18 years or older at the time of signing the informed&#xD;
             consent form (ICF).&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks from the time of enrollment as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          -  Oxygen saturation ≥ 92% on room air for all indications.&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1.&#xD;
&#xD;
          -  Patients with brain metastases are eligible if certain criteria are met.&#xD;
&#xD;
          -  Availability of fresh or archival tumor tissue&#xD;
&#xD;
          -  Patients must have a minimum of 6 months of response to any nonpalliative&#xD;
             cancer-directed treatment&#xD;
&#xD;
        Dose Expansion Inclusion Criteria (Non-Small Cell Lung Cancer):&#xD;
&#xD;
          -  Histologically confirmed diagnosis of stage IV NSCLC.&#xD;
&#xD;
          -  Patients must have a minimum of 6 months of response to any nonpalliative&#xD;
             cancer-directed treatment.&#xD;
&#xD;
          -  Patients with actionable mutations with approved targeted therapy in NSCLC are&#xD;
             excluded. Testing for mutations should be performed per standard of care.&#xD;
&#xD;
          -  Must not have received anti-cancer therapy for treatment of metastatic lung cancer&#xD;
&#xD;
          -  Must not have received prior immunotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of an investigational agent or an investigational device within 28 days before&#xD;
             administration of first dose of study drug(s).&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Patients who have an active autoimmune disease&#xD;
&#xD;
          -  History of allergy or hypersensitivity to study drug components&#xD;
&#xD;
          -  Evidence of clinically significant interstitial lung disease or active, noninfectious&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Prior surgery or radiotherapy within 14 days of therapy.&#xD;
&#xD;
          -  For Dose Optimization Cohort 1 only: Chemotherapy or biological therapy within 28 days&#xD;
             of enrollment. Targeted therapy (e.g., tyrosine kinase inhibitors) within 14 days of&#xD;
             enrollment. Patients with ongoing AEs related to prior cancer therapies will be&#xD;
             excluded.&#xD;
&#xD;
          -  Participant's inability to adhere to or tolerate protocol or study procedures&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Nektar Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nektar Recruitment</last_name>
    <phone>855-482-8676</phone>
    <email>StudyInquiry@nektar.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medical Affairs Department</last_name>
    <email>medicalaffairs@nektar.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Highlands Oncology Group, PA - North Hills</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Augusta University - Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University (SIU) School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center (KUMC)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Park Nicollet - Frauenshuh Cancer Center</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63156</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Duke Clinical Research Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Inova Melanoma and Skin Cancer Center</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Cancer Care</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Froedtert &amp; the Medical College of Wisconsin Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Epworth HealthCare</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Saint-Quentin</name>
      <address>
        <city>Saint Quentin</city>
        <zip>2100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Spandau</name>
      <address>
        <city>Berlin</city>
        <zip>13585</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken München-Gauting</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>LungenClinic Grosshansdorf</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lungenklinik Hemer</name>
      <address>
        <city>Hemer</city>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Luca di Lucca</name>
      <address>
        <city>Lucca</city>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Monza - Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20090</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran Canaria</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>HM Universitario Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 1, 2017</study_first_submitted>
  <study_first_submitted_qc>May 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NKTR-214</keyword>
  <keyword>Metastatic Non-Small Cell Lung Cancer</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Keytruda®</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Bempegaldesleukin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

